Ratings Lotus Pharmaceutical Co., Ltd.

Equities

End-of-day quote Taiwan S.E. Other stock markets 2024-09-11			5-day change	1st Jan Change
270.50 ^TWD	-2.70%		-1.28%	-0.55%

09-06	Lotus Pharmaceutical Board to Acquire Product Rights of Vietnamese Firm	MT
09-05	Lotus Pharmaceutical Co., Ltd. agreed to acquire Intellectual Property rights of Alpha Choay from Sanofi Vietnam Shareholding Company for $50 million.	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company's enterprise value to sales, at 4.21 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Source: Surperformance

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	LOTUS PHARMACEUTICAL CO., LTD.				2.23B
	ELI LILLY AND COMPANY				829B
	NOVO NORDISK A/S				583B
	JOHNSON & JOHNSON				397B
	ABBVIE INC.				344B
	MERCK & CO., INC.				291B
	ROCHE HOLDING AG				255B
	ASTRAZENECA PLC				248B
	NOVARTIS AG				232B
	AMGEN INC.				177B
	Average				335.85B
	Weighted average by Cap.